HOME >> MEDICINE >> NEWS
Broad-based vaccination of wild mice could help reduce lyme disease risk in humans

nown as erythema migrans, as well as fatigue, chills and fever, headache, muscle aches and joint pain. Early treatment prevents the development of more debilitating symptoms. Lyme disease is most commonly found in the northeastern, mid-Atlantic and upper north-central regions of the United States, as well as parts of northwestern California.

In their study, the research team took aim at the larval form of the blacklegged tick, the crucial stage during which a tick becomes infected with B. burgdorferi. Normally, uninfected tick larvae pick up the bacterium the first summer of their two-year life cycle while taking their first blood meal from infected small animals, such as the white-footed mouse. The white-footed mouse is considered a key animal reservoir for Lyme disease. One year later, after the larva develops into a nymph, it feeds on a second animal host, possibly a human, infecting that host. Roughly 90 percent of human infections are contracted from nymphal ticks.

The researchers' goal was to reduce the level of B. burgdorferi infection in nymphal ticks. By vaccinating a large sample of white-footed mice, the researchers hypothesized, fewer tick larvae would become infected the first summer and, in turn, fewer nymphs would be capable of transmitting the disease to humans the following summer.

Throughout the summers of 1998 and 2001, researchers trapped and vaccinated a total of more than 900 mice in 12 different forested sites in Connecticut--six unique sites each summer. In half of the sites, mice received injections of active vaccine; in the other six sites, mice received a placebo.

The vaccine contained a recombinant protein--called OspA--normally found on the outer surface of B. burgdorferi in ticks but not in mice. The vaccine is based on one previously used in humans and currently used in dogs. When an infected nymph feeds on an immunized mouse, the animal's antibodies kill the bacterium inside the nymph, preventing the ny
'"/>

Contact: Jennifer Wenger
jwenger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
13-Dec-2004


Page: 1 2 3 4

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. Influenza vaccination programmes for children in USA and Canada based on little evidence
3. Flu vaccination benefits people of any age with high-risk medical conditions
4. Flu vaccination impact on elderly deaths may be over-estimated
5. Risk factors affect parents attitudes about STD vaccinations
6. Parents comfortable with vaccination for sexually transmitted infections for adolescent children
7. Study documents decline in rare paralytic disorder linked to influenza vaccination
8. Annual vaccination against influenza associated with decreased risk of death in elderly
9. Hib infections on the rise in adults despite child vaccination programme
10. Most physicians agree that widespread routine influenza vaccination for young children is feasible
11. Childhood vaccination coverage affected by temporary suspension of hepatitis B vaccine

Post Your Comments:
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: